Navigation Links
Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
Date:8/18/2008

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of CombiMatrix Corporation (Nasdaq: CBMX) with a BUY rating and an $18.00 price target. CombiMatrix is a life sciences company focused on developing and commercializing in vitro genetic diagnostics that leverage its core CustomArray technology.

Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides high quality distribution, research and trade execution for institutional and retail clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies.

Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report at 888-293-1800.

This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. For these and other reasons, the investments discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Transactions in securities mentioned herein may be effected only in those states where such securities are qualified for sale.

Any statements nonfactual in nature herein constitute only current opinions or estimates, represent only the current judgment of the author(s), and are subject to change without notice. This report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from the results described in the forward-looking statements. Emerging Growth Equities, Ltd. (or one of its affiliates) or their partners, officers, directors, analysts, employees or customers may have an interest in the securities mentioned herein and may make purchases or sales as principal or agent of these securities, or their derivatives, while this report is in circulation. A partner, employee, analyst, officer, or director of Emerging Growth Equities, Ltd. (or one of its affiliates) may serve as a director or consultant for any company mentioned herein. Emerging Growth Equities, Ltd. (or one of its affiliates) may from time to time perform investment banking services for, or solicit investment banking business or other business from, any company mentioned herein. Additional information on the securities discussed herein is available on request.

Emerging Growth Equities, Ltd. is a member of the Financial Industry Regulatory Authority, CRD number 47040.


'/>"/>
SOURCE Emerging Growth Equities, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
2. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
3. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
4. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
7. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
8. Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano
9. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
10. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
11. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2017)... ... June 15, 2017 , ... DuPont Industrial ... will be speaking at Bloomberg’s 2017 Sustainable Business Summit: Seattle this ... and sustainability officials on a panel titled “Developing a Corporate Renewables Strategy.” ...
(Date:6/14/2017)... ... June 14, 2017 , ... The Thailand Board ... announces that they’re co-hosting a delegation from Thailand at BIO 2017 in San ... industry gathering in the world, regroups more than 1,100 biotech companies, academic institutions, ...
(Date:6/14/2017)... ... 14, 2017 , ... Cynvenio Biosystems, Inc. a ... distribution agreements for Cynvenio’s ClearID line of blood tests that support targeted treatment selection ... ClearID available immediately in Israel, Greece, Argentina, and South Korea. , ...
(Date:6/14/2017)... ... June 14, 2017 , ... ... 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) ... diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):